

Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells

Yong-Fang Jiang, Yan He, Guo-Zhong Gong, Jun Chen, Chun-Yan Yang, Yun Xu

Yong-Fang Jiang, Yan He, Guo-Zhong Gong, Jun Chen, Chun-Yan Yang, Yun Xu, Center for Liver Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China

Supported by the Public Health Department Foundation of Hunan province, China, No. Y02-42

Correspondence to: Dr Yong-Fang Jiang, Center for Liver Diseases, Second Xiangya Hospital, Central South University, No 139 Renmin Zhong Street, Changsha 410011, Hunan Province, China. jiangyongfang@hotmail.com

Telephone: +86-731-5524222-2263 **Fax:** +86-731-4896920

Received: 2004-03-30 **Accepted:** 2004-05-13

Abstract

AIM: To construct a recombinant murine CD40 ligand (mCD40L) eukaryotic expression vector for gene therapy and target therapy of hepatocellular carcinoma (HCC).

METHODS: mCD40L cDNA was synthesized by RT-PCR with the specific primers and directly cloned into T vector to generate middle recombinant. After digestion with restriction endonuclease, the target fragment was subcloned into the multi-clone sites of the eukaryotic vector. The constructed vector was verified by enzyme digestion and sequencing, and the product expressed was detected by RT-PCR and immunofluorescence methods.

RESULTS: The full-length mCD40L-cDNA was successfully cloned into the eukaryotic vector through electrophoresis, and mCD40L gene was integrated into the genome of infected H22 cells by RT-PCR. Murine CD40L antigen molecule was observed in the plasma of mCD40L-H22 by indirect immuno-fluorescence staining.

CONCLUSION: The recombined mCD40L eukaryotic expression vector can be expressed in H22 cell line. It provides experimental data for gene therapy and target therapy of hepatocellular carcinoma.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Hepatocellular carcinoma; Murine CD40 ligand; Plasmids; Genetic vectors

Jiang YF, He Y, Gong GZ, Chen J, Yang CY, Xu Y. Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells. *World J Gastroenterol* 2005; 11(2): 182-186

<http://www.wjgnet.com/1007-9327/11/182.asp>

INTRODUCTION

In China, the incidence of HCC is very high^[1], and surgical operation, chemotherapy, and interventional therapy are the common therapies. But only a few patients of early stage without

extrahepatic malignancy are indicated for operation, and for the advanced cases, chemotherapy and interventional therapy usually can not achieve a satisfactory effect. Therefore, it is urgent to find a novel strategy to prevent the proliferation of malignant cells. It is a hot spot at present to study immunogene therapy.

CD40 ligand (CD40L) is a 39 kD glycoprotein which is expressed on lymphocytes and non-lymphocytic leukocytes^[2]. It is a member of the tumor necrosis factor family, and binds to CD40 on the membrane of antigen-presenting cells (APC)^[3,4]. CD40-CD40L interaction plays a crucial role in the activation of APC and the initiation of both humoral and cellular immune responses^[5-7].

Thus, gene transfer of CD40L has been proposed as an efficient means to treat malignancies^[8]. CD40L may be used as a target molecule for immunotherapy or prophylaxis against HCC. For this purpose, we constructed the recombinant mCD40L eukaryotic expression vector, and expected that it would provide experimental data for the treatment of HCC.

MATERIALS AND METHODS

Cell lines and culture condition

Mouse splenocytes were obtained from female BALB/c mice. Cells were maintained in RPMI 1640 medium, supplemented with 10 mL/L FCS and 1 mmol/L glutamine, activated with Con A for 5 h. H22 cell line was provided by the Department of Biochemistry, Fourth Military Medical University, Xi'an, China. Cells were maintained in RPMI 1640 medium, supplemented with 10 mL/L FCS, 1 mmol/L glutamine, and 100 kU/L penicillin.

Plasmids and strain

The eukaryotic expression vector pcDNA3.1⁺ was presented by Dr. Chun Deng, Michigan College, USA. The T vector pUCm-T was provided by the Bioasia, Shanghai. *E. coli* strain JM109 was purchased from Invitrogen Life Technologies (Burlington, ON, Canada).

Construction of recombinant mCD40L eukaryotic expression vector

A cDNA fragment coding for the full open reading frame of mouse CD40L gene was cloned by reverse transcription polymerase chain reaction (RT-PCR) from Con A stimulated mouse spleen cells using Taq polymerase. Two primers specific for the mouse CD40L gene were used, namely, the sense primer (5'-GACGCTAGCATGATAGAAACATACAGCCAACT-3') and the antisense primer (5'-GCC GAA TTC TCA GAG TTT GAG TAA GCC AAA AGA-3'). PCR conditions included 1 cycle at 94 °C for 5 min for pre-denaturation; 35 amplification cycles each consisting of denaturation at 94 °C for 60 s, annealing at 60 °C for 50 s, and extension at 72 °C for 90 s; followed by a further extension at 72 °C for 10 min. The cloned cDNA fragment was ligated into the pUCm-T vector to form pUCm-T-CD40L. The cDNA fragment of mCD40L from pUCm-T-mCD40L vector was further subcloned into the pcDNA3.1⁺ to form eukaryotic expression vector pcDNA3.1⁺-mCD40L. The recombinant expression vector pcDNA3.1⁺-mCD40L was amplified in *E. coli* JM109 and then extracted by Wizard® Plus SV Minipreps

DNA Purification System (Promega, USA) according to the manufacturer's instructions.

Identification of recombinant mCD40L eukaryotic expression vector

The full-length mCD40L-cDNA was retrieved from the gel. pcDNA3.1⁺-mCD40L was digested by *Nhe*I and *Eco*RI according to the afore-mentioned methods. The digested products were evaluated with 1.0% agarose gel electrophoresis. The full-length mCD40L-cDNA was successfully inserted into pcDNA3.1⁺.

Nucleotide sequence analysis

The correct plasmids of recombinant mCD40L eukaryotic expression vector identified by the restriction analysis were sequenced using fluorescent dideoxynucleotides (Bioasia, Shanghai, China) on an automated DNA sequencer (ABI Prism 377). The sequences were compared with the published cDNA sequence^[4].

Transfection of H22 cells

H22 cells were transfected with pcDNA3.1⁺-mCD40L by liposome, LipofectamineTM 2000 (Gibco, USA). All the procedures were performed according to the guidance of the reagent. After 24-h exposure, cells were washed three times with medium and cultured in normal medium. Twenty-four hours after medium exchange, cells were selected in medium containing 800 µg/mL G418 (Gibco, USA). After 18 d of selection, G418-resistant clones were selected randomly from the surviving colonies. H22 cells were also transfected with pcDNA3.1⁺ as control group, and H22 cells that were not transfected also served as control.

Detection of mCD40L expression by RT-PCR

To demonstrate the expression of mCD40L mediated by pcDNA3.1⁺-mCD40L vector, total cellular RNA was extracted from the H22 cells. Synthesis and amplification of mCD40L cDNA were performed using RT-PCR. The cDNA was amplified with primers specific for mCD40L and the synthesis conditions according to the afore-mentioned methods.

Detection of mCD40L expression by immunofluorescence

The transfected cells were stabilized with 10 g/L formaldehydum polymerisatum for 30 min at 4 °C, and blocked with 100 g/L bovine serum albumin (BSA) for 1 h at room temperature, then coated with rabbit anti-mouse CD40L antibody (Dako, Japan) for 45 min at 37 °C, followed by goat anti-rabbit IgG-FITC (Boster, Wuhan) for 30 min at 37 °C. The antibody-coated cells were observed under a fluorescence microscope (Optiphot XIF, Nikon, Japan) within 24 h.

RESULTS

Evaluation of pcDNA3.1⁺-mCD40L

To demonstrate whether the full-length mouse CD40L-cDNA was inserted into the multi-clone sites of pcDNA3.1⁺ correctly, pcDNA3.1⁺-mCD40L was digested by *Nhe*I and *Eco*RI and evaluated with electrophoresis. Figure 1 shows that mCD40L-cDNA was successfully inserted into pcDNA3.1⁺.




Figure 1 Electrophoresis of recombinant plasmid pcDNA3.1⁺-mCD40L. Lanes 1 and 5: DNA molecular weight marker; lane 2: The RT-PCR product of mCD40L; lane 3: pcDNA3.1⁺-mCD40L digested with *Nhe*I and *Eco*RI, pcDNA3.1⁺ in the upper, full-length mCD40L-cDNA in the lower; and lane 4: pcDNA3.1⁺-mCD40L not digested with *Nhe*I and *Eco*RI.




Figure 2 The sequencing map of pcDNA3.1⁺-mCD40L with M13F primer.




Figure 3 Sequencing map of pcDNA3.1⁺-mCD40L with M13R primer.

```

GGAGACCCAAGCTG GCTAGCATGATAGAAACATACAGCCAACCTTCCCCAGATCCG
TGGCAACTGGACTTCCAGCGAGCATGAAGATTTTTATGATTTACTTACTGTTTTCTT
ATCACCCAAATGATTGGATCTGTGCTTTTTGCTGTGTATCTTCATAGAAGATTGGATA
AGGTCGAAGAGGAAGTAAACCTTCATGAAGATTTTGTATTCATAAAAAACCTAAAGAG
ATGCAACAAAGGAGAAGGATCTTTATCCTTGCTGAACTGTGAGGAGATGAGAAGGCA
ATTTGAAGACCTTGCAAGGATATAACGTTAAACAAAGAAGAGAAAAAGAAAACAG
CTTTGAAATGCAAAGAGGTGATGAGGATCCTCAAATTGCAGCACACGTTGTAAGCGA
AGCCAACAGTAATGCAGCATCCGTTCTACAGTGGGCCAAGAAAGGATATTATACCAT
GAAAAGCAACTTGTAATGCTTGAAAATGGGAAACAGCTGACGGTTAAAAGAGAAG
GACTCTATTATGTCTACACTCAAGTCACCTTCTGCTCTAATCGGGAGCCTTCGAGTCA
ACGCCCATTCATCGTCGGCCTCTGGCTGAAGCCCAGCAGTGGATCTGAGAGAATCTT
ACTCAAGGCGGCAAATACCCACAGTTCCTCCAGCTTTGCGAGCAGCAGTCTGTTCA
CTTGGGCGGAGTGTGTTGAATTACAAGCTGGTGCTTCTGTGTTTGTCAACGTGACTGA
AGCAAGCCAAGTGATCCACAGATTGGCTTCTCATTTTTGGCTTACTCAAACCTCTG
AGAATTTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGT

```

Figure 4 Nucleotide splicing sequence result of pcDNA3.1⁺-mCD40L with DNASTAR software analysis.

Recombinant plasmid pcDNA3.1⁺-mCD40L sequence analysis

Plasmid DNA was extracted. The correct plasmids identified by restriction analysis were sequenced. The result of sequencing is shown in Figures 2-4. It demonstrated that integral mCD40L cDNA containing start codon, stop codon and endonuclease sites was cloned into eukaryotic expression vector pcDNA3.1⁺.

RT-PCR

RT-PCR analysis showed that 0.8 kb fragments corresponding

to the mCD40L cDNA were amplified with the total cellular RNA only from pcDNA3.1⁺-mCD40L-transduced H22 cells, but not from the cells transduced with pcDNA3.1⁺ (Figure 5).

Immunofluorescence staining of transfected cells

The transfected cells were coated with mCD40L antibody and fluorescent antibody. Under fluorescence microscopes, it was observed that the fluorescence staining was positive in the cytoplasm of H22 cells transfected with pcDNA3.1⁺-mCD40L and negative in the controls (Figure 6).




Figure 5 mCD40L gene expression in H22 cells by RT-PCR. Lanes 1 and 8: marker; Lane 2: negative control; Lanes 3-6: RT-PCR products from transfected H22 cells; Lane 7: RT-PCR product from BALB/C mouse splenocytes.




Figure 6 H22 cells transfected with pcDNA3.1⁺-mCD40L. The fluorescence staining in the cytoplasm was positive. $\times 400$.

DISCUSSION

Hepatocellular carcinoma (HCC) is a very common malignancy in China, and has a very poor prognosis^[1]. Despite recent increases in therapeutic options, such as total vascular exclusion (TVE) technique used in hepatectomies of advanced and complicated hepatocellular carcinomas, combined multimodal interventional therapies which have revealed their advantages as compared with any single therapeutic regimen and play more important roles in treating unresectable HCC^[9], and hepatic arterial infusion chemotherapy which may be a useful alternative for the treatment of patients with advanced HCC^[10], percutaneous cryoablation which offers a safe and possibly curative treatment option for patients with HCC that can not be surgically removed^[11], HCC remains one of the leading causes of death. The malignancies are often resistant to chemotherapy and metastasize to distant organs in the early stage of the disease. Even after the primary tumor is removed surgically, relapse at the primary or distant sites frequently occurs. Surgical resection itself may not accelerate cancer dissemination and increase postoperative recurrence significantly^[12]. Preoperative level of circulating VEGF mRNA, especially isoform VEGF 165, plays a significant role in the prediction of postoperative recurrence of HCC. Gene therapy provides new possibilities for the treatment of incurable diseases, including hepatocellular carcinoma^[13].

However, the host immunity frequently fails to eliminate malignant tumors caused either by the lack of recognizable tumor antigens or by the inability of tumor antigens to stimulate an effective immune response^[14,15], thus most malignant tumors evade host immune surveillance. The use of gene therapy with immunostimulatory molecules aiming at enhancing antitumoral

immunity has emerged as a promising new approach to treat cancer^[16,17].

CD40L-CD40 interactions on membranes of APC, including dendritic cells (DCs), can activate APC, promote effective antigen presentation, express costimulatory and adhesion molecules, and up-regulate cytokine and chemokine production. For instance, CD40L-CD40 interactions strongly promote Th1 differentiation and provide a strong signal for interleukin (IL)-12 production, even in the presence of Th2 cytokines^[18]. The endogenous production of IL-12 resulting from CD40L-CD40 interaction may play a role in the persistence of antitumor effects^[19]. CD40 activation through CD40L-CD40 interaction may be used as a potential treatment tool of malignant neoplasms^[20]. The rationale for transducing tumor cells with CD40L is to convert these cells into stimulators of APC, an effect leading to enhanced presentation of tumor antigens to T cells and activation of antitumor immune responses. In fact, CD40L-CD40 interactions have been demonstrated to overcome tumor-specific CD4⁺ and CD8⁺ tolerance and induce antitumor immunity^[21,22]. It remains possible that combining CD40L gene with another immunotherapeutic modality (*e.g.*, IL-12, CD80) or with a tumor associated antigen (*e.g.*, alpha fetoprotein, AFP) gene therapy would be still better. Using mCD40L gene or combining with IL-12 gene transduced leukemia cell therapy for chronic lymphocytic leukemia (CLL)^[23], primary B-CLL^[24,25] and acute leukemia^[26] has provided encouraging results. Treatment not only appears capable of inducing a cellular anti-leukemia immunity, but also may have a direct effect on leukemia cells by inducing latent sensitivity to Fas (CD95)-dependent leukemia cell apoptosis^[26]. Recently, many investigators have reported that *ex vivo* transduction of tumor cells with the mCD40L gene or *in vivo* transfer of the mCD40L gene is able to induce antitumor immunity against different tumor cell lines in subcutaneous tumor models, such as lung cancer^[27,28], colon cancer^[29,30], urologic malignancies^[31-33], melanoma^[34] and malignant mesothelioma^[35]. In HCC, Schmitz *et al.*^[8] used adenovirus-mediated CD40 ligand gene therapy for orthotopic hepatocellular carcinoma, and demonstrated that it abrogated HCC cell tumorigenicity when expressing mCD40L gene, and led to complete tumor eradication and long-term survival in most of the treated animals. Yanagi *et al.*^[36] showed that Flt3L and CD40L significantly induced antitumor immunity against MH134 cells presumably through both innate and adaptive immunity. These data reveal that administration of mCD40L gene might provide an efficient and safe treatment for HCC.

In summary, mCD40L gene has shown its profound effect on HCC treatment in animal models. In our experiment, we could successfully construct the recombinant mCD40L eukaryotic expression vector, and the mCD40L expressed in H22 cells effectively. This, we believe, provides experimental data for gene therapy and immunotherapy of HCC.

REFERENCES

- 1 **Tang ZY**. Hepatocellular carcinoma-cause, treatment and metastasis. *World J Gastroenterol* 2001; **7**: 445-454
- 2 **Mach F**, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. *Proc Natl Acad Sci USA* 1997; **94**: 1931-1936
- 3 **Grewal IS**, Flavell RA. CD40 and CD154 in cell-mediated immunity. *Annu Rev Immunol* 1998; **16**: 111-135
- 4 **Roy M**, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4⁺ T cells. *J Immunol* 1993; **151**: 2497-2510
- 5 **Ridge JP**, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-

- killer cell. *Nature* 1998; **393**: 474-478
- 6 **Bennett SR**, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* 1998; **393**: 478-480
- 7 **Schoenberger SP**, Toes RE, van der Voort EI, Oeffringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. *Nature* 1998; **393**: 480-483
- 8 **Schmitz V**, Barajas M, Wang L, Peng D, Duarte M, Prieto J, Qian C. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. *Hepatology* 2001; **34**: 72-81
- 9 **Miyazaki M**, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Ohtsuka M, Togawa A, Kimura F. An approach to intrapericardial inferior vena cava through the abdominal cavity, without median sternotomy, for total hepatic vascular exclusion. *Hepatogastroenterology* 2001; **48**: 1443-1446
- 10 **Mazzanti R**, Giallombardo AL, Mini E, Nobili S, Neri B, Arena U, Pantaleo P, Fabbioni V, Ghilardi M, Gattai R, Bandettini L. Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. *Dig Liver Dis* 2004; **36**: 278-285
- 11 **Qian GJ**, Chen H, Wu MC. Percutaneous cryoablation after chemoembolization of liver carcinoma: report of 34 cases. *Hepatobiliary Pancreat Dis Int* 2003; **2**: 520-524
- 12 **Chen WT**, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. *Eur J Surg Oncol* 2004; **30**: 414-420
- 13 **Ruiz J**, Mazzolini G, Sangro B, Qian C, Prieto J. Gene therapy of hepatocellular carcinoma. *Dig Dis* 2001; **19**: 324-332
- 14 **Chouaib S**, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. *Immunol Today* 1997; **18**: 493-497
- 15 **Gabrilovich DI**, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nat Med* 1996; **2**: 1096-1103
- 16 **Ruiz J**, Qian C, Drozdak M, Prieto J. Gene therapy of viral hepatitis and hepatocellular carcinoma. *J Viral Hepat* 1999; **6**: 17-34
- 17 **Melero I**, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. *Trends Immunol* 2001; **22**: 113-115
- 18 **Bullens DM**, Kasran A, Thielemans K, Bakkus M, Ceuppens JL. CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. *Scand J Immunol* 2001; **53**: 455-463
- 19 **Harada M**, Tamada K, Abe K, Yasumoto K, Kimura G, Nomoto K. Role of the endogenous production of interleukin 12 in immunotherapy. *Cancer Res* 1998; **58**: 3073-3077
- 20 **Ottaiano A**, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR. CD40 activation as potential tool in malignant neoplasms. *Tumori* 2002; **88**: 361-366
- 21 **Sotomayor EM**, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HL. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through *in vivo* ligation of CD40. *Nat Med* 1999; **5**: 780-787
- 22 **Diehl L**, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Oeffringa R, Toes RE. CD40 activation *in vivo* overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. *Nat Med* 1999; **5**: 774-779
- 23 **Wierda WG**, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. *Blood* 2000; **96**: 2917-2924
- 24 **Wendtner CM**, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, Schweighofer C, Perabo L, Danhauser-Riedl S, Baumert J, Hiddemann W, Hallek M, Buning H. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. *Blood* 2002; **100**: 1655-1661
- 25 **von Bergwelt-Baildon M**, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in B-CLL. *Ann Oncol* 2004; **15**: 853-857
- 26 **Saudemont A**, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, Bauters F, Fenaux P, Quesnel B. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. *Leukemia* 2002; **16**: 1637-1644
- 27 **Noguchi M**, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. *Cancer Gene Ther* 2001; **8**: 421-429
- 28 **Tada Y**, O-Wang J, Yu L, Shimozato O, Wang YQ, Takiguchi Y, Tatsumi K, Kuriyama T, Takenaga K, Sakiyama S, Tagawa M. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. *Cancer Gene Ther* 2003; **10**: 451-456
- 29 **Sun Y**, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J. *In vivo* gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. *Gene Ther* 2000; **7**: 1467-1476
- 30 **Buning C**, Kruger K, Sieber T, Schoeler D, Schriever F. Increased expression of CD40 ligand on activated T cells of patients with colon cancer. *Clin Cancer Res* 2002; **8**: 1147-1151
- 31 **Loskog A**, Totterman TH, Bohle A, Brandau S. *In vitro* activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. *Cancer Gene Ther* 2002; **9**: 846-853
- 32 **Loskog A**, Bjorkland A, Brown MP, Korsgren O, Malmstrom PU, Totterman TH. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. *J Urol* 2001; **166**: 1093-1097
- 33 **Hussain SA**, Ganesan R, Hiller L, Murray PG, el-Magraby MM, Young L, James ND. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. *Br J Cancer* 2003; **88**: 586-592
- 34 **Peter I**, Naweath M, Kamarashev J, Odermatt B, Mezzacasa A, Hemmi S. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. *Cancer Gene Ther* 2002; **9**: 597-605
- 35 **Friedlander PL**, Delaune CL, Abadie JM, Toups M, LaCour J, Marrero L, Zhong Q, Kolls JK. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. *Am J Respir Cell Mol Biol* 2003; **29**: 321-330
- 36 **Yanagi K**, Nagayama Y, Nakao K, Saeki A, Matsumoto K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells *in vivo*. *Int J Oncol* 2003; **22**: 345-351